Basit öğe kaydını göster

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

dc.contributor.authorKaradogan, I.
dc.contributor.authorSonmez, M.
dc.contributor.authorGulbas, Z.
dc.contributor.authorTekgunduz, E.
dc.contributor.authorKaya, A. H.
dc.contributor.authorOzbalak, M.
dc.contributor.authorKaynar, L.
dc.contributor.authorYildirim, R.
dc.contributor.authorArat, M.
dc.contributor.authorTastemir, N.
dc.contributor.authorBekoz, H.
dc.contributor.authorKaradurmus, N.
dc.contributor.authorPaydas, S.
dc.contributor.authorTurker, A.
dc.contributor.authorToptas, T.
dc.contributor.authorTuglular, T. Firatli
dc.contributor.authorFerhanoglu, B.
dc.contributor.authorDemirkol, O.
dc.contributor.authorDemirkurek, H. C.
dc.contributor.authorYilmaz, M.
dc.contributor.authorToprak, S. K.
dc.contributor.authorKoseoglu, F. D.
dc.contributor.authorDemirkaya, M.
dc.contributor.authorBarista, I.
dc.contributor.authorHacioglu, S. Kabukcu
dc.contributor.authorDogu, M. H.
dc.contributor.authorOzcan, M.
dc.contributor.authorYuksel, M. Kurt
dc.contributor.authorTurgut, M.
dc.contributor.authorAbali, H.
dc.contributor.authorOzkocaman, V.
dc.contributor.authorTanrikulu, F. Pepedil
dc.date.accessioned2021-03-03T11:02:47Z
dc.date.available2021-03-03T11:02:47Z
dc.date.issued2017
dc.identifier.citationBekoz H., Karadurmus N., Paydas S., Turker A., Toptas T., Tuglular T. F. , Sonmez M., Gulbas Z., Tekgunduz E., Kaya A. H. , et al., "Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience", ANNALS OF ONCOLOGY, cilt.28, sa.10, ss.2496-2502, 2017
dc.identifier.issn0923-7534
dc.identifier.otherav_25cf1c15-6345-46cf-8c22-8e8e956b7c69
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/30315
dc.identifier.urihttps://doi.org/10.1093/annonc/mdx341
dc.description.abstractBackground: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile.
dc.language.isoeng
dc.subjectTıp
dc.subjectOnkoloji
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.titleNivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
dc.typeMakale
dc.relation.journalANNALS OF ONCOLOGY
dc.contributor.departmentİstanbul Medipol Üniversitesi , ,
dc.identifier.volume28
dc.identifier.issue10
dc.identifier.startpage2496
dc.identifier.endpage2502
dc.contributor.firstauthorID246823


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster